자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapies and medications are not effective. A customized treatment could be the answer.

Cue is an intervention platform that converts sensors that are passively gathered from smartphones into customized micro-interventions to improve mental health. We examined the most effective-fitting personalized ML models to each person, using Shapley values to determine their feature predictors. The results revealed distinct characteristics that deterministically changed mood over time.

Predictors of Mood

Depression is a leading cause of mental illness in the world.1 Yet only half of those affected receive treatment. To improve outcomes, healthcare professionals must be able to identify and treat patients who are most likely to benefit from certain treatments.

A customized depression treatment is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit the most from specific treatments. They are using sensors on mobile phones as well as a voice assistant that incorporates artificial intelligence, and other digital tools. With two grants awarded totaling more than $10 million, they will use these technologies to identify the biological and behavioral factors that determine responses to antidepressant medications as well as psychotherapy.

So far, the majority of research on predictors for depression treatment effectiveness has focused on sociodemographic and clinical characteristics. These include demographic variables like age, sex and educational level, clinical characteristics like symptom severity and comorbidities, and biological indicators such as neuroimaging and genetic variation.

While many of these aspects can be predicted from the data in medical records, only a few studies have used longitudinal data to determine the factors that influence mood in people. Few studies also take into account the fact that moods can differ significantly between individuals. Therefore, it is important to devise methods that permit the identification and quantification of individual differences between mood predictors and treatment options for depression effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can identify different patterns of behavior and emotions that vary between individuals.

The team also created an algorithm for machine learning to model dynamic predictors for each person's mood for depression. The algorithm combines the individual differences to create an individual "digital genotype" for each participant.

This digital phenotype was found to be associated with CAT DI scores, a psychometrically validated scale for assessing severity of symptom. The correlation was not strong however (Pearson r = 0,08; BH adjusted P-value 3.55 x 10 03) and varied greatly between individuals.

Predictors of symptoms

Depression is the most common cause of disability around the world, but it is often misdiagnosed and untreated2. In addition, a lack of effective treatments and stigma associated with depressive disorders stop many people from seeking help.

To aid in the development of a personalized treatment plan to improve treatment, identifying the factors that predict the severity of symptoms is crucial. However, current prediction methods are based on the clinical interview, which is not reliable and only detects a limited number of symptoms associated with depression.2

Machine learning is used to blend continuous digital behavioral phenotypes captured by sensors on smartphones and a validated online mental health tracker (the Computerized Adaptive Testing Depression Inventory the CAT-DI) along with other indicators of severity of symptoms has the potential to improve the accuracy of diagnosis and the effectiveness of treatment for depression treatment without drugs. Digital phenotypes permit continuous, high-resolution measurements. They also capture a wide variety of distinct behaviors and patterns that are difficult to capture using interviews.

The study involved University of California Los Angeles (UCLA) students who were suffering from mild to severe depression symptoms. participating in the Screening and Treatment for Anxiety and Depression (STAND) program29, which was developed under the UCLA Depression Grand Challenge. Participants were referred to online assistance or medical care based on the severity of their depression. Patients with a CAT DI score of 35 or 65 were given online support with an instructor and those with a score 75 were sent to clinics in-person for psychotherapy.

At the beginning of the interview, participants were asked an array of questions regarding their personal characteristics and psychosocial traits. These included sex, age, education, work, and financial situation; whether they were divorced, partnered or single; the frequency of suicidal ideas, intent or attempts; as well as the frequency with which they drank alcohol. Participants also rated their degree of postpartum depression treatment near me symptom severity on a scale of 0-100 using the CAT-DI. CAT-DI assessments were conducted every week for those that received online support, and every week for those who received in-person support.

Predictors of Treatment Reaction

Research is focusing on personalized depression treatment. Many studies are focused on finding predictors, which can aid clinicians in identifying the most effective drugs to treat each patient. Pharmacogenetics, in particular, is a method of identifying genetic variations that affect the way that our bodies process drugs. This lets doctors select the medication that will likely work best for each patient, while minimizing the amount of time and effort required for trials and errors, while avoid any negative side negative effects.

Another promising approach is to develop prediction models combining the clinical data with neural imaging data. These models can be used to determine which variables are most predictive of a specific outcome, such as whether a drug will improve mood or symptoms. These models can be used to determine the patient's response to a treatment, allowing doctors to maximize the effectiveness.

A new generation of studies uses machine learning methods such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables and improve the accuracy of predictive. These models have been proven to be useful for predicting treatment outcomes such as the response to antidepressants. These models are getting more popular in psychiatry, and it is expected that they will become the norm for the future of clinical practice.

In addition to ML-based prediction models, research into the mechanisms behind depression continues. Recent research suggests that the disorder is associated with dysfunctions in specific neural circuits. This suggests that the treatment for situational depression treatment will be individualized based on targeted treatments that target these neural circuits to restore normal functioning.

One way to do this is by using internet-based programs that offer a more individualized and tailored experience for patients. For instance, one study found that a program on the internet was more effective than standard care in alleviating symptoms and ensuring the best quality of life for those with MDD. A controlled study that was randomized to a personalized treatment for depression revealed that a significant percentage of patients experienced sustained improvement as well as fewer side effects.

Predictors of adverse effects

A major issue in personalizing depression treatment is predicting which antidepressant medications will have minimal or no side effects. Many patients are prescribed a variety of medications before finding a medication that is effective and tolerated. Pharmacogenetics offers a fascinating new avenue for a more efficient and specific approach to choosing antidepressant medications.

There are many variables that can be used to determine the antidepressant that should be prescribed, including genetic variations, phenotypes of the patient like gender or ethnicity, and the presence of comorbidities. To identify the most reliable and reliable predictors for a particular treatment, controlled trials that are randomized with larger sample sizes will be required. This is because it could be more difficult to identify moderators or interactions in trials that only include a single episode per person instead of multiple episodes spread over time.

Additionally, the estimation of a patient's response to a particular medication is likely to require information on the symptom profile and comorbidities, as well as the patient's previous experience of its tolerability and effectiveness. At present, only a handful of easily measurable sociodemographic variables as well as clinical variables seem to be consistently associated with response to MDD. These include age, gender and race/ethnicity as well as BMI, SES and the presence of alexithymia.

Many challenges remain in the application of pharmacogenetics to treat depression. First it is necessary to have a clear understanding of the genetic mechanisms is essential as well as a clear definition of what is a reliable indicator of treatment response. Ethics such as privacy and the responsible use genetic information must also be considered. In the long run pharmacogenetics can be a way to lessen the stigma associated with mental health treatment and to improve the outcomes of those suffering with depression. But, like all approaches to psychiatry, careful consideration and implementation is essential. At present, the most effective option is to offer patients various effective depression treatment plan cbt medications and encourage them to speak with their physicians about their concerns and experiences.